Compare M&T Bank Corporation (MTB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Neurocrine Biosciences Inc — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.37B), while Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B). The key difference: M&T Bank Corporation is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and M&T Bank Corporation pays a 2.52% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MTB | NBIX | |
|---|---|---|
Market Cap | $34.37B | $15.77B |
Sector | Financials | Health |
52-Week High | $254.09 | $185.50 |
52-Week Low | $178.63 | $123.10 |
Dividend Yield | 2.52% | — |
Enterprise Value | — | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.35 surpassing the $4.66 forecast. Revenue growth is steady, reaching $9.63 billion in 2025, and the net income margin is strong at 30.85%. A quarterly dividend of $1.50 per share was recently declared, payable in September 2026.
The outlook is positive, supported by earnings beats and a consensus price target of $261.62, implying nearly 10% upside. Key risks include a negative net cash flow of -$2.01 billion in 2025 and rising debt levels, while analyst sentiment is mixed with a 'Hold' consensus amid macroeconomic uncertainty.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
